Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes...
6 KB (374 words) - 22:45, 1 April 2023
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults...
14 KB (1,161 words) - 05:20, 7 April 2024
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It contains...
9 KB (495 words) - 13:47, 7 September 2024
or 12 weeks of sofosbuvir/velpatasvir, or if certain antiviral mutations are present, 12 weeks of sofosbuvir/velpatasvir/voxilaprevir (when certain antiviral...
109 KB (11,864 words) - 01:35, 14 November 2024
(glecaprevir + pibrentasvir) Ravidasvir Sofosbuvir Sofosbuvir/velpatasvir (sofosbuvir + velpatasvir) Ledipasvir/sofosbuvir (ledipasvir + sofosbuvir) Ribavirin...
67 KB (4,835 words) - 08:21, 11 November 2024
J05AP54 Elbasvir and grazoprevir J05AP55 Sofosbuvir and velpatasvir J05AP56 Sofosbuvir, velpatasvir and voxilaprevir J05AP57 Glecaprevir and pibrentasvir...
6 KB (538 words) - 04:59, 18 December 2023
first generics. The company's commercially available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir...
5 KB (232 words) - 10:23, 8 March 2024
part of some second-line treatments. Sofosbuvir in combination with velpatasvir is recommended for all genotypes with a cure rate greater than 90%, and...
64 KB (5,828 words) - 23:44, 21 October 2024
inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion...
4 KB (132 words) - 07:32, 24 November 2024
Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir# Ombitasvir/paritaprevir/ritonavir# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir# Sofosbuvir/velpatasvir/voxilaprevir...
26 KB (2,541 words) - 07:34, 24 November 2024
(sofosbuvir and ledipasvir) Epclusa (sofosbuvir and velpatasvir) Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) Zepatier (elbasvir and grazoprevir)...
55 KB (6,733 words) - 21:23, 24 October 2024
Afdhal; Stuart K Roberts; et al. (17 November 2015). "Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection". The New England Journal of Medicine...
6 KB (901 words) - 04:55, 26 October 2024
decreased. Later single-pill combinations were Epclusa (with velpatasvir) and Vosevi (with velpatasvir and voxilaprevir). For the fiscal year 2017, Gilead Sciences...
79 KB (7,678 words) - 01:41, 11 November 2024
unlimited access to highly active anti-hepatitis C medication (sofosbuvir/velpatasvir) for its HCV-infected Medicaid and incarcerated populations. "Louisiana...
8 KB (553 words) - 10:20, 20 November 2024
Mollison, Lindsay C.; Sulkowski, Mark (31 December 2015). "Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection". New England Journal of Medicine...
12 KB (1,195 words) - 09:58, 15 June 2024
combination with velpatasvir, ABT-493 in combination with ABT-530, and grazoprevir in combination with elbasvir, of which velpatasvir, ABT-530 and elbasvir...
50 KB (5,211 words) - 01:38, 14 November 2024
(glecaprevir + pibrentasvir) Sofosbuvir Sofosbuvir/velpatasvir (sofosbuvir + velpatasvir) No listings in this section. No listings in this section...
38 KB (2,574 words) - 03:03, 15 July 2024
NS5A inhibitors of this class—daclatasvir, ombitasvir, elbasvir and velpatasvir—have been subsequently approved. All direct-acting antivirals are used...
33 KB (3,798 words) - 21:57, 16 May 2024
Hodgkin lymphoma Atezolizumab Genentech urothelial carcinoma Sofosbuvir/velpatasvir Gilead Sciences chronic hepatitis C virus genotypes 1, 2, 3, 4, 5 or...
34 KB (180 words) - 17:05, 14 October 2024
available, are not considered as first-line therapies: Sofosbuvir/Velpatasvir Sofosbuvir/Velpatasvir/Voxilaprevir Barriers to care exist when discussing therapeutic...
28 KB (3,550 words) - 01:37, 14 November 2024
2015 Elbasvir, approved on January 28, 2016 in a FDC with grazoprevir Velpatasvir, approved on June 28, 2016 in a FDC with sofosbuvir and on July 17, 2017...
10 KB (1,179 words) - 06:28, 28 March 2024
Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir". Gastroenterology. 153 (6): 1694–1695. doi:10.1053/j...
53 KB (6,064 words) - 16:19, 13 August 2024
treatment including active substances - sofosbuvir, daclatasvir, ledipasvir, velpatasvir. The results of using antiviral therapy reach 97% of fully healed patients...
22 KB (2,250 words) - 01:17, 11 November 2024